Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains

Laryngoscope

Volumn 118, Issue 4, 2008, Pages 599-604

  Altman, Kenneth W ^a   Chhaya, Vina ^b   Hammer, Neal D ^b   Pavlova, Sylvia ^b   Vesper, Benjamin J ^b   Tao, Lin ^b   Radosevich, James A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Aerodigestive tract; Bacteria; H+ K+ ATPase; Minimum inhibitory concentration; Pantoprazole; Proton pump inhibitor

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONFORMATION; CONTROLLED STUDY; DRUG EFFECT; GRAM STAINING; INOCULATION; LACTOBACILLUS; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; COLONY COUNT, MICROBIAL; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS FERMENTUM; LACTOBACILLUS PLANTARUM; MICROBIAL SENSITIVITY TESTS; MOUTH;

EID: 41849146451     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e318161f9bf     Document Type: Article

References (17)

1. Jensen RT. Consequences of long-term proton pump inhibitor blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4-19.
2. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Inter Med 2007;167:950-955.
3. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-2995.
4. The bacterial flora of humans. In: Todar's Online Textbook of Bacteriology. Available at: http://textbookofbacteriology.net/normalflora. html. Accessed November 13, 2007.
5. Pavlova SI, Tao L. In vitro inhibition of commercial douche products against vaginal microflora. Infect Dis Obstect Gynecol 2000;8:99-104.
6. Garrity G, Brenner DJ, Krieg NR, et al., eds. Bergey's Manual of Systemic Bacteriology, Vol. 2. New York: Springer Verlag; 2005.
7. Suzuki H, Miyazawa M, Nagahashi S, et al. Rabeprazole treatment attenuated Heliobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils. J Gastroenterol Hepatol 2003;18:787-795.
8. Lins RL, Otoul C, De Smedt F, Coupez R, Stockis A. Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int J Clin Pharmacol Ther 2007;45:47-54.
9. Cone EJ, Huestis MA. Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci 2007;1098:51-103.
10. Baron C, Coombes B. Targeting bacterial secretion systems: benefits of disarmament in the microcosm. Infect Disord Drug Targets 2007;7:19-27.
11. Wang K, Lin HJ, Perng CL, et al. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology 2004;51:1540-1543.
12. Altman KW, Waltonen JD, Hammer ND, Haines GK III, Radosevich JA. Proton pump expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg 2005;133:718-724.
13. +-ATPase proton pump. Ann Otol Rhinol Laryngol 2007;116:229-234.
14. Nutrition and growth of bacteria. In: Todar's Online Textbook of Bacteriology. Available at: http://textbookofbacteriology.net/nutgro.html. Accessed November 13, 2007.
15. Young G, Krasner RI, Yudkofsky PL. Interactions of oral strains of Candida albicans and lactobacilli. J Bacteriol 1956;72:525-529.
16. Hatakka K, Ahola AJ, Yli-Knuuttila H, et al. Probiotics reduce the prevalence of oral Candida in the elderly: a randomized controlled trial. J Dent Res 2007;86:125-130.
17. Selimoglu MA, Selimoglu E, Kurt A. Nasal mucociliary clearance and nasal and oral pH in patients with insulin-dependent diabetes. Ear Nose Throat J 1999;78:585-588.